- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04267822
Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV (REVIRAL2)
Randomized, Double-blind, Placebo-controlled Trial of the Safety, Tolerability, and Efficacy of RV521 in the Treatment of Adult Subjects Who Have Undergone Hematopoietic Cell Transplantation (HCT) With a Documented Upper Respiratory Tract Infection (URTI) With Respiratory Syncytial Virus (RSV)
Study Overview
Status
Intervention / Treatment
Detailed Description
The purpose of this study is to compare the viral load, safety, tolerability, and clinical efficacy of RV521 compared to placebo. This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled study. Up to 200 adult subjects with a documented symptomatic RSV URTI who have undergone HCT within 1 year of randomization and who are moderately to severely immunocompromised will be randomized.
Qualified subjects will be randomized in a 1:1 ratio to receive RV521 capsules or matching placebo twice daily for 10 days. After the completion of the 10-day double-blind treatment period, subjects will be followed for an additional 28 days. Study drug may be taken on an outpatient or inpatient basis, depending on clinical status and site practices. Randomization will be stratified by type of HCT graft and ALC count. There are 9 clinic visits planned for this study.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Has undergone autologous or allogeneic HCT using any conditioning regimen within 1 year of randomization. Subjects who have undergone HCT more than 1 year before Randomization are eligible if all other inclusion/exclusion criteria are satisfied and under at least one of the following conditions:
- Diagnosed with Chronic Graft-vs-Host Disease (GVHD), or
- Has used systemic corticosteroids in the 30 days prior to RSV infection
- Has moderate to severe immunocompromise, defined as a score ≥ 5 on the ISI-RSV and/or an ALC of ≤ 500 cells/ mm3
- Documentation of positive RSV infection in the upper airway
Exclusion Criteria:
- Use of non-marketed investigational agents within 30 days, OR use of an investigational monoclonal anti-RSV antibodies within 4 months or 5 half-lives of screening, whichever is longer, OR use of any investigational RSV vaccines after HCT.
- Receiving a prescription, OTC, or herbal medication that is a potent inducer or inhibitor of CYP3A4, within 2 weeks of Randomization.
- Receiving a prescription, OTC, or herbal medication that is a substrate of CYP3A4 with a narrow therapeutic index where monitoring blood levels is not possible.
- Known chronic infection with hepatitis B, C, or HIV.
- Is in the pre-engraftment period during RSV infection.
- Admitted to the hospital primarily for lower respiratory tract disease of any cause as determined by the Investigator.
- Any condition requiring mechanical ventilation or vasopressor support at the time of randomization.
- Clinically significant bacteremia or fungemia within 5 days prior to Screening that has not been adequately treated.
- Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated.
- Excessive nausea/vomiting at Screening or an inability to swallow capsules.
- Elevation of hepatic enzymes or renal compromise.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: RV521 Capsules
RV521 is formulated as a dry powder blend of RV521 drug substance with mannitol as excipient.
They are a white, opaque capsule and administered orally.
|
Each RV521 dose is four 50 mg dry powder blend capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Other Names:
|
Placebo Comparator: RV521 Placebo Capsules
RV521 placebo capsules will contain mannitol and microcrystalline cellulose only.
They are a white, opaque capsule and administered orally.
|
Each placebo dose is four capsules, taken orally twice daily for 10 days (20 doses total; 80 capsules total)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with a progression to Lower Respiratory Tract Complication (LRTC) during the study
Time Frame: Pre-dose baseline (Day 1) through Visit 8 (Day 28)
|
Progression to LRTC during the study defined as one of the following:
|
Pre-dose baseline (Day 1) through Visit 8 (Day 28)
|
Change in RSV nasal viral load (via RT-qPCR)
Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
RSV change measured by the time-weighted average (DAVG) viral load using RT qPCR
|
Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of participants who experience AEs, TEAEs, SAEs and withdrawals due to TEAEs
Time Frame: First dose of study drug through Visit 8 (Day 28)
|
Safety analyses will include a summary of AEs, including but not limited to n (%) of subjects in each treatment group and overall.
|
First dose of study drug through Visit 8 (Day 28)
|
Evaluate safety and tolerability of RV521 by assessing changes from baseline in systolic and diastolic BP (vital sign parameters)
Time Frame: Baseline through Visit 8 (Day 28)
|
BP will be collected in mm Hg.
Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
|
Baseline through Visit 8 (Day 28)
|
Evaluate safety and tolerability of RV521 by assessing changes from baseline in body temperature (vital sign parameters)
Time Frame: Baseline through Visit 8 (Day 28)
|
Body Temperature will be collected in degrees Fahrenheit (°F) or degrees Celsius (°C).
Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
|
Baseline through Visit 8 (Day 28)
|
Evaluate safety and tolerability of RV521 by assessing changes from baseline in respiration rate (vital sign parameters)
Time Frame: Baseline through Visit 8 (Day 28)
|
Respiration rate will be measured in breaths per minute.
Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
|
Baseline through Visit 8 (Day 28)
|
Evaluate safety and tolerability of RV521 by assessing changes from baseline in pulse/heart rate (vital sign parameters)
Time Frame: Baseline through Visit 8 (Day 28)
|
Heart rate will be measured in beats per minute.
Quantitative variables will be summarized used the statistics n, mean, standard deviation, median, minimum and maximum.
|
Baseline through Visit 8 (Day 28)
|
Evaluate safety and tolerability of RV521 by assessing changes from baseline weight/BMI
Time Frame: Baseline through Visit 8 (Day 28)
|
Weight and height will be collected and combined to report BMI
|
Baseline through Visit 8 (Day 28)
|
Evaluate the proportion of subjects with changes and shifts in hematology/clinical chemistry/urinalysis laboratory values (laboratory tests read by a central lab) from baseline.
Time Frame: Collected at Visit 2/Day 1 (pre-dose), Visit 4/Day 3, Visit 6/Day 14 and Visit 8/Day 28
|
Results at each visit will be summarized using the statistics n, mean, standard deviation, median, minimum and maximum.
Also, change from baseline will also be summarized by post baseline visits.
|
Collected at Visit 2/Day 1 (pre-dose), Visit 4/Day 3, Visit 6/Day 14 and Visit 8/Day 28
|
Evaluate the proportion of subjects with changes in ECG measurements and changes in clinical impression from baseline
Time Frame: Measurements will be taken at Day 1/Visit 2 (pre-dose and at 5-hours post-dose), on Day 3/Visit 4 (at 5 hours post-dose), and at Visit 6 (Day 14)
|
ECGs will be taken with a centrally supplied ECG machine and electronically transmitted to a central ECG repository. ECG will only be evaluated by the Investigator for normal, abnormal NCS and abnormal CS. Parameters collected will be:
Results at each visit will be summarized using the statistics: n (number of observations), mean, SD, median, minimum and maximum. |
Measurements will be taken at Day 1/Visit 2 (pre-dose and at 5-hours post-dose), on Day 3/Visit 4 (at 5 hours post-dose), and at Visit 6 (Day 14)
|
Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by RT-qPCR
Time Frame: Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)
|
Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory.
Viral load will be assessed at intervals from nasal swabs by RT-qPCR.
|
Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)
|
Relationship between plasma exposures of RV521 and RSV viral loads measured in nasal swabs by CBIA
Time Frame: Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)
|
Nasal swabs will be collected for analysis of viral load and RSV F protein gene sequencing at a central laboratory.
Viral load will be assessed at intervals from nasal swabs by CBIA.
|
Pre-dose baseline (Day 1) and every visit through Visit 8 (Day 28)
|
Mean change in RSV viral load assessed via CBIA
Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
change measured by the time weighted average (DAVG) viral load using CBIA
|
Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
Mean change from baseline in viral RNA shedding
Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.
|
Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
Proportion of subjects who no longer shed RSV assessed by both RT-qPCR and CBIA at each timepoint
Time Frame: Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
RSV assessed via nasal swabs collected at each visit and analyzed at a central laboratory.
|
Pre-dose baseline (Day 1) through study completion; up to Visit 8 (Day 28)
|
Time to improvement in RSV-related symptoms
Time Frame: Daily from baseline (Day 1) through Visit 8 (Day 28)
|
Defined as all symptoms present at initiation of therapy are mild or no longer present.
(absent/resolved)
|
Daily from baseline (Day 1) through Visit 8 (Day 28)
|
Time to total resolution of all RSV-related symptoms
Time Frame: Daily from baseline (Day 1) through Visit 8 (Day 28)
|
Defined as all symptoms are no longer present.
|
Daily from baseline (Day 1) through Visit 8 (Day 28)
|
Proportion of days with lowest daily SpO2 ≥ 90% on room air
Time Frame: Daily from baseline (Day 1) through Visit 8 (Day 28)
|
SpO2 measured at every visit.
For subjects on oxygen or who are mechanically ventilated may have this waived.
|
Daily from baseline (Day 1) through Visit 8 (Day 28)
|
Number of days where supplementary oxygen was required
Time Frame: Baseline (Day 1) through Visit 8 (Day 28)
|
Use of daily supplementary oxygen will be collected throughout the study.
|
Baseline (Day 1) through Visit 8 (Day 28)
|
Proportion of subjects who require hospitalization during the study
Time Frame: Baseline (Day 1) through Visit 8 (Day 28)
|
Daily hospitalization utilization will be collected
|
Baseline (Day 1) through Visit 8 (Day 28)
|
Mean number of days of hospitalization during the study
Time Frame: Baseline (Day 1) through Visit 8 (Day 28)
|
Daily hospitalization utilization will be collected
|
Baseline (Day 1) through Visit 8 (Day 28)
|
Proportion of subjects requiring ICU
Time Frame: Baseline (Day 1) through Visit 8 (Day 28)
|
Daily ICU utilization will be collected
|
Baseline (Day 1) through Visit 8 (Day 28)
|
Mean number of days in ICU
Time Frame: Baseline (Day 1) through Visit 8 (Day 28)
|
Daily ICU utilization will be collected
|
Baseline (Day 1) through Visit 8 (Day 28)
|
Proportion of subjects requiring mechanical ventilation
Time Frame: Baseline (Day 1) through Visit 8 (Day 28)
|
Daily mechanical ventilation requirements will be collected
|
Baseline (Day 1) through Visit 8 (Day 28)
|
Number of subjects who experience death (all-cause mortality)
Time Frame: First dose of study drug through Visit 8 (Day 28)
|
Patient outcome will be followed and collected
|
First dose of study drug through Visit 8 (Day 28)
|
Number of subjects who experience death attributable to LRTC
Time Frame: First dose of study drug through Visit 8 (Day 28)
|
Patient outcome will be followed and collected
|
First dose of study drug through Visit 8 (Day 28)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REVC006
- C5241011 (Other Identifier: Pfizer)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lower Resp Tract Infection
-
University of SouthamptonNot yet recruitingLower Resp Tract Infection
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingLower Resp Tract Infection
-
Centre Hospitalier Universitaire VaudoisCompletedLower Resp Tract InfectionSwitzerland
-
BioFire Diagnostics, LLCCompletedLower Resp Tract InfectionUnited States
-
Assistance Publique - Hôpitaux de ParisUnknownLower Resp Tract Infection | Human Metapneumovirus InfectionFrance
-
Duke UniversityCompletedCOVID-19 | SARS-CoV-2 | Lower Resp Tract Infection | Coronavirus | Influenza -Like Illness | Upper Resp Tract InfectionUnited States
-
University Hospital, CaenCompletedLower Resp Tract Infection | Ultrasound Therapy; ComplicationsFrance
-
PfizerTerminatedLower Resp Tract Infection | Respiratory Syncytial Virus (RSV)Spain, Malaysia, Israel, Hungary, Poland, Taiwan, Costa Rica, United Kingdom, Thailand, Argentina, Canada, Chile, Korea, Republic of, New Zealand, Panama
-
Centre Hospitalier Universitaire VaudoisUniversity of Witwatersrand, South Africa; Ecole Polytechnique Fédérale de... and other collaboratorsRecruitingPneumonia | Tuberculosis | Lower Resp Tract InfectionBenin, Mali, South Africa
-
University of PittsburghPatient-Centered Outcomes Research InstituteRecruitingPneumonia | Sepsis | Covid19 | Lower Resp Tract InfectionUnited States
Clinical Trials on RV521 oral tablet
-
PfizerCompletedRespiratory Syncytial Virus InfectionsUnited States
-
PfizerCompletedRespiratory Syncytial Virus InfectionsUnited Kingdom
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
PfizerCompleted
-
PfizerRecruitingRespiratory Syncytial Virus InfectionsUnited States, Israel, Korea, Republic of, Japan, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
University of OxfordNovo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United Kingdom